Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and PHILADELPHIA , Nov. 26, ... demanding and unforgiving environments. Human exploration of space requires ... to ensure mission safety and success, and prevent potential ... for mission success, little is known about how cognition ... cognition are primarily affected. Now, Penn Medicine ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... announced today that applications for AccelerateBaltimore™ (AB) 2015 ... you have a big idea?,” asked ETC’s President ... about it. AccelerateBaltimore helps you and your big ... 13 weeks.” Interested game changers with “big ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 SonaCare ... Focused Ultrasound (HIFU) devices, recently participated in the ... Renal Mass 360° .” Key opinion leaders in ... advances related to small renal masses while attendees ... different ablative technologies in hands-on labs. Attendees at ...
(Date:11/26/2014)... The Pittcon marketing department is pleased ... exposition mobile app, Pittcon 2015 . ... App Store for iOS and Android devices and the ... during and after the event. It acts as an ... technical sessions, Conferee Networking sessions and short courses. , ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2
... Extensive Pharmaceutical Experience ... throughout the Region, ... that it has appointed Abdulkader,Al-Mehyar Moh,d Basheer Halawy as sales ... the new sales program with orders for,20,000 units., "These ...
... Biotechnology,International, Inc. (OTC Bulletin Board: YGYB; "Yongye" ... distributor of nutrients for plants and,animals in ... that it closed a,private placement financing with ... Management, pursuant to which the Company issued,6,073,006 ...
... Calif., Sept. 10 Forterus,Inc. (OTC Bulletin Board: ... Inc., its behavioral healthcare subsidiary, is the first,in ... for,individuals with a genetic predisposition for addictive behavior., ... centers in California, A,Better Tomorrow is constantly striving ...
Cached Biology Technology:BioElectronics Corp Aggressively Expands Sales into Middle East 2BioElectronics Corp Aggressively Expands Sales into Middle East 3Yongye Biotechnology International Raises $9.4 Million in Private Placement 2Yongye Biotechnology International Raises $9.4 Million in Private Placement 3A Better Tomorrow Treatment Center Inc., Forterus Inc.'s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior 2
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... of consuming dark chocolate and cocoa mounts, there has ... products deliver the most beneficial compounds, known as flavanols, ... the levels of cocoa flavanols. In ... of conventional production methods of cocoa beans on the ...
... , This release is available in French ... is opening today on the grounds of the Botanical Garden. ... University and the Botanical Garden and the Montral Insectarium, two ... cutting-edge scientific facilities for research into biodiversity, its preservation and ...
... by James Henderson, assistant professor of biomedical and ... of Engineering and Computer Science (LCS) and researcher ... memory polymers to provide greater insight into how ... Most cell biomechanics research has examined cell behavior ...
Cached Biology News:Study clarifies the role of cocoa bean handling on flavanol levels 2The University of Montreal Biodiversity Centre opens 2The University of Montreal Biodiversity Centre opens 3Syracuse University research team shapes cell behavior research 2
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... adsorbents are macroporous polystyrene beads for hydrophobic ... area for adsorbing organics of molecular weight ... beads are useful for the adsorption of ... example, the removal of detergents such as ...
... : Fusion protein corresponding to ... human Mi-2 Formulation: 0.7M Tris-glycine, ... sodium azide, containing 30% glycerol ... immunoblot on Hela nuclear extract ...
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ... 150 mM NaCl, 10 mM ... 50% glycerol, pH 7.5. Recognizes ... protein kinase 2 (MAPKAPK-2) protein ...
Biology Products: